Theravance Biopharma (TBPH) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts TBPH Hot Sheet
Join SI Premium – FREE
Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $16.21 million.
For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- Bnccorp, Inc. (BNCC) Tops Q3 EPS by 94c
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
